Overview

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

Status:
Completed
Trial end date:
2018-08-23
Target enrollment:
Participant gender:
Summary
To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
Phase:
N/A
Details
Lead Sponsor:
Melissa Toyos
Melissa Toyos, MD
Collaborator:
Bausch & Lomb Incorporated
Treatments:
Bromfenac
Nepafenac
Ophthalmic Solutions
Pharmaceutical Solutions